| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
5,804 |
4,491 |
$336K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
1,864 |
969 |
$282K |
| 99215 |
Prolong outpt/office vis |
963 |
826 |
$81K |
| 87481 |
|
608 |
486 |
$66K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,461 |
1,280 |
$52K |
| 87529 |
|
625 |
492 |
$29K |
| 87500 |
|
1,084 |
779 |
$23K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,253 |
813 |
$21K |
| 87631 |
|
214 |
193 |
$20K |
| 87640 |
|
1,194 |
850 |
$18K |
| 87653 |
|
806 |
552 |
$16K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
717 |
537 |
$14K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
618 |
465 |
$14K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
546 |
435 |
$13K |
| 87563 |
|
350 |
274 |
$9K |
| 87511 |
|
440 |
342 |
$8K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
83 |
82 |
$7K |
| 87581 |
|
300 |
258 |
$7K |
| 87486 |
|
296 |
258 |
$7K |
| 87641 |
|
318 |
264 |
$7K |
| 87541 |
|
264 |
233 |
$6K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
121 |
89 |
$4K |
| 99458 |
|
44 |
41 |
$3K |
| 99457 |
|
69 |
66 |
$3K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
16 |
15 |
$2K |
| 81003 |
|
1,368 |
1,235 |
$2K |
| 99205 |
Prolong outpt/office vis |
17 |
17 |
$2K |
| 87501 |
|
62 |
39 |
$2K |
| 36415 |
Collection of venous blood by venipuncture |
942 |
865 |
$2K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
80 |
57 |
$1K |
| 92552 |
|
114 |
105 |
$1K |
| 81513 |
|
22 |
22 |
$1K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
36 |
36 |
$748.53 |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
17 |
16 |
$572.95 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
36 |
35 |
$522.00 |
| 99173 |
|
142 |
135 |
$312.00 |
| 87498 |
|
20 |
18 |
$289.52 |
| 81025 |
|
78 |
73 |
$277.78 |
| 96127 |
|
46 |
41 |
$158.69 |
| 87634 |
|
78 |
57 |
$0.00 |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
16 |
15 |
$0.00 |